-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Ipamorelin 10mg is a synthetic research peptide studied in relation to growth hormone secretagogue receptor research, ghrelin receptor pathway models, GH axis signalling, pituitary pathway research and endocrine signalling studies.
Ipamorelin is commonly described as a pentapeptide and ghrelin mimetic. PubChem lists Ipamorelin with the molecular formula C38H49N9O5 and describes it as a pentapeptide with growth hormone secretagogue activity, acting through the ghrelin receptor, also known as the growth hormone secretagogue receptor or GHSR.
This product is supplied for laboratory research use only. It is not a medicine, supplement, growth hormone booster, anti-ageing product, muscle growth product, fat loss product, recovery product, bodybuilding product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Ipamorelin |
| Common research names | Ipamorelin, NNC 26-0161 |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Growth Hormone Research / GHSR Pathway Research |
| Common research interest | Ghrelin receptor signalling, GHSR pathway research, GH axis models and endocrine signalling |
| Peptide type | Synthetic pentapeptide |
| Main receptor interest | Growth hormone secretagogue receptor, also known as GHSR or ghrelin receptor |
| Molecular formula | C38H49N9O5 |
| Molecular weight | Approximately 711.9 g/mol |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, muscle growth, fat loss, anti-ageing or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Ipamorelin | Synthetic growth hormone secretagogue research peptide | Studied in relation to GHSR and GH axis pathway research |
| Pentapeptide structure | Five-amino-acid peptide | Commonly discussed as Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Ghrelin mimetic activity | GHSR pathway research | Studied in relation to ghrelin receptor signalling models |
| GHSR pathway interest | Growth hormone secretagogue receptor pathway | Used in endocrine and pituitary signalling research |
| Molecular formula | C38H49N9O5 | Listed by PubChem for Ipamorelin |
| Molecular weight | Approximately 711.9 g/mol | Useful for laboratory concentration and molar calculation planning |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Product identity, sequence, purity, salt form and batch information should always be confirmed through supplier documentation and the Certificate of Analysis. Researchers should not rely on product name alone when confirming peptide identity.
Ipamorelin is studied as a growth hormone secretagogue receptor pathway research peptide. In research settings, GHSR-related compounds are examined for how they interact with the ghrelin receptor pathway and influence downstream endocrine signalling models.
The ghrelin receptor, also known as GHSR-1a, is a key receptor in ghrelin signalling research. A PubMed Central review describes acyl-ghrelin as binding GHSR-1a with nanomolar affinity and discusses the receptor’s signalling role in health and disease research.
Ipamorelin is also relevant to anti-doping and compliance discussions. WADA’s Prohibited List includes growth hormone secretagogues and their mimetics, with ipamorelin named as an example under the growth hormone releasing factors category.
This should be understood as research and regulatory context only. It should not be used as a claim that a research-use Ipamorelin 10mg vial is approved, safe or effective for growth hormone enhancement, body composition, recovery, anti-ageing, bodybuilding or human performance.
| Research Area | Ipamorelin |
| Main research category | Growth hormone secretagogue pathway research |
| Common development name | NNC 26-0161 |
| Peptide length | Pentapeptide |
| Main receptor interest | GHSR / ghrelin receptor |
| Parent pathway context | Ghrelin mimetic and growth hormone secretagogue research |
| Downstream research interest | GH axis and endocrine signalling models |
| Common comparison | CJC-1295, CJC-1295 No DAC, GHRP-2, GHRP-6 and Hexarelin |
| Anti-doping context | Listed by WADA as a prohibited growth hormone secretagogue example |
| Product limitation | Research use only, not approved for human use |
| Feature | Ipamorelin | CJC-1295 No DAC |
| Research class | Growth hormone secretagogue research peptide | GHRH analogue research peptide |
| Main pathway | Ghrelin receptor / GHSR pathway | GHRH receptor pathway |
| GH axis position | Secretagogue pathway research | Growth hormone-releasing hormone pathway research |
| Common research pairing | Often discussed with GHRH analogues in pathway research | Often discussed with Ipamorelin in combination research |
| Common SEO risk | GH boosting, bodybuilding and anti-ageing claims | GH boosting, fat loss and anti-ageing claims |
| Safer positioning | GHSR pathway research peptide | Modified GRF 1-29 research peptide |
| Feature | Ipamorelin | CJC-1295 with DAC |
| Research class | GHSR pathway research peptide | Long-acting GHRH analogue research peptide |
| Main receptor pathway | GHSR / ghrelin receptor | GHRH receptor |
| DAC status | No DAC structure | Includes Drug Affinity Complex |
| Research pathway | Secretagogue pathway research | Growth hormone-releasing hormone pathway research |
| Structure | Pentapeptide | Modified GHRH analogue |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | Ipamorelin | GHRP-6 |
| Research class | Growth hormone secretagogue peptide | Growth hormone releasing peptide |
| Main pathway | GHSR / ghrelin receptor pathway | GHSR / ghrelin receptor pathway |
| Peptide type | Pentapeptide | Hexapeptide |
| Common research discussion | Selective GHSR pathway research | Older GHRP pathway research |
| Common SEO risk | GH boosting and anti-ageing claims | Appetite, GH boosting and bodybuilding claims |
| Safer positioning | GHSR endocrine pathway research | GHRP pathway research |
| Product | Safer Research Positioning |
| Ipamorelin 10mg | GHSR and ghrelin receptor pathway research |
| CJC-1295 No DAC 5mg | Modified GRF 1-29 and GHRH receptor pathway research |
| CJC-1295 with DAC 10mg | Longer-acting GHRH analogue research |
| CJC-1295 No DAC + Ipamorelin 10mg | Dual-pathway GHRH and GHSR research blend |
| Tesamorelin | GHRH analogue and metabolic pathway research |
| HGH 10IU | Somatropin and GH receptor pathway research reference |
These products should not be written as if they are interchangeable. Ipamorelin is positioned around GHSR and ghrelin receptor pathway research, while CJC-1295 and Tesamorelin relate to GHRH pathway research.
| Common Online Claim | Safer Research-Use Wording |
| Growth hormone boost | Studied in GHSR and GH axis research models |
| Muscle growth | Not an approved or appropriate product claim |
| Fat loss | Not an approved or appropriate product claim |
| Anti-ageing | Not an approved or appropriate product claim |
| Better sleep | Not an approved or appropriate product claim |
| Recovery | Better framed as GH axis pathway research, not a human benefit |
| Bodybuilding | Not suitable for research-use product positioning |
| Performance enhancement | Not an approved or appropriate product claim |
| Hormone optimisation | Not suitable for a research-use product page |
Ipamorelin 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for growth hormone enhancement, muscle growth, fat loss, anti-ageing, recovery, sleep, bodybuilding, performance enhancement, body transformation, hormone therapy or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Ipamorelin 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling Ipamorelin 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Ipamorelin peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps confirm the product is Ipamorelin |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, peptide identity and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible peptide mix-up | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from CJC-1295, GHRP-6 and HGH products |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
Ipamorelin 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Peptide identity | Confirmation that the product is Ipamorelin |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or GH-axis products are confused with one another.
Because Ipamorelin is commonly discussed online in relation to growth hormone, anti-ageing, bodybuilding, fat loss and recovery, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, hormone manipulation or performance enhancement.
Sport Integrity Australia lists Ipamorelin under growth hormone secretagogues that are prohibited in and out of competition, so athlete, performance, recovery and bodybuilding positioning should be avoided entirely on a compliant research-use page.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide identity | Helps verify product accuracy |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research pathways from human benefit claims | Avoids unsafe or misleading product positioning |
| Avoid sport and performance wording | Reduces anti-doping and compliance risk |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a growth hormone booster | Creates human-use and compliance risk |
| Never make muscle growth or fat loss claims | Not an approved or appropriate product claim |
| Never make anti-ageing or recovery claims | Not an approved or appropriate product claim |
| Never imply hormone therapy use | Not suitable for a research-use product page |
| Never market to athletes or bodybuilders | Creates anti-doping and human-use risk |
| Never describe it as performance enhancement | Misleading and not appropriate |
| Never confuse Ipamorelin with CJC-1295 | They act on different research pathways |
| Never copy handling notes from HGH products | HGH is a different product class |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
Ipamorelin is a synthetic research peptide commonly described as a pentapeptide and ghrelin mimetic. It is studied in relation to the growth hormone secretagogue receptor, also known as GHSR or the ghrelin receptor.
Yes. Ipamorelin is commonly described as a pentapeptide, meaning it contains five amino acid residues.
Ipamorelin is commonly studied in relation to GHSR, ghrelin receptor signalling, GH axis pathway research, pituitary signalling models and broader endocrine pathway research.
No. Ipamorelin is usually positioned around GHSR and ghrelin receptor pathway research. CJC-1295 is usually positioned around GHRH receptor pathway research. They relate to different receptor pathways.
No. This research product is not approved or supplied for muscle growth, fat loss, anti-ageing, recovery, bodybuilding, hormone therapy, performance enhancement or human administration. It should be described only as a laboratory research product.
Ipamorelin is listed by Sport Integrity Australia under growth hormone secretagogues that are prohibited in and out of competition. WADA’s Prohibited List also names ipamorelin as an example of a growth hormone secretagogue and mimetic.
No. Ipamorelin is a synthetic pentapeptide studied in GHSR pathway research. HGH is human growth hormone, a protein hormone. They are different product classes and should not be positioned as interchangeable.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, sequence and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Ipamorelin compound profile | Useful background on Ipamorelin identity, sequence description, molecular formula and molecular weight. |
| Ghrelin receptor signalling review | Useful background on GHSR-1a and ghrelin receptor signalling biology. |
| WADA Prohibited List | Important anti-doping context showing ipamorelin listed as an example of a prohibited growth hormone secretagogue. |
Research Use Only: Ipamorelin 10mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use, growth hormone enhancement, hormone therapy, muscle growth, fat loss, anti-ageing, recovery, sleep, bodybuilding, athletic performance, body enhancement or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation and qualified laboratory protocols.
